Living Immunotherapies
Pioneering Differentiated TCR-T Therapies for Cancer Patients

About Medigene
Medigene is an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Medigene was founded by scientists with the commitment to create breakthrough therapies to fundamentally improve the lives of cancer patients.
Medigene’s End-to-End Platform
The basis of Medigene’s differentiation is our end-to-end platform of multiple, combinable, exclusive and proprietary technologies. These technologies build in both the potential of enhancing our TCR-T drug products from a safety and / or efficacy perspective as well as through optimizing our development processes at multiple sequential stages of development, from target screening, through TCR generation and optimization and ultimately into clinical development.

Target
Screening

TCR
Generation & optimization

TCR-T Therapy armoring & enhancement

Manufacturing & Process Improvement

Clinical Development
Latest News
Our Partners
We aim to enter strategic partnerships with interested parties to share the transformative potential of cancer immunotherapies with partners who truly believe in innovation.




